Abbott makes strategic investment in small neuro biotech
This article was originally published in Scrip
Executive Summary
Abbott Biotech Ventures has made a strategic investment of undisclosed value in privately held company, NeuroGenetic Pharmaceuticals, to expedite the development of a small molecule candidate for the prevention of Alzheimer's disease. Although the Abbott investment is likely to be less than $3 million, NeuroGenetic’s management believes that it provides industry validation for its approach.